文献速递脑血管病

S100B血清浓度作为机械取栓后替代结局指标的作用

Role of S100B Serum Concentration as a Surrogate Outcome Parameter After Mechanical Thrombectomy.
PubMed 文献 · Neurology · 2021-10-11

这项前瞻性两中心研究纳入171例因大血管闭塞所致急性大脑中动脉梗死并接受机械取栓的患者,于术后第2天检测S100B血清浓度。结果显示S100B与梗死体积相关,且预后良好组(mRS 0-1)第2天S100B中位数低于预后不良组(mRS 2-6)。S100B可消除mRS评估中的侧化偏倚,有望成为客观替代结局指标。

要点

  • 取栓后第2天S100B血清浓度与梗死体积相关,可反映缺血组织损伤程度。
  • 预后良好组(90天mRS 0-1)S100B中位数低于预后不良组(mRS 2-6)。
  • 较低S100B、较低24小时NIHSS和较年轻年龄独立关联于良好预后。

核心结论

  • 机械取栓后S100B血清浓度可反映缺血组织损伤范围,并能快速评估且不依赖脑影像和临床结局量表。
  • 经进一步前瞻性验证后,S100B可能成为临床常规和介入试验中的客观替代结局指标。

研究设计与样本

  • 前瞻性两中心研究,招募因大血管闭塞所致急性大脑中动脉梗死并接受机械取栓的患者。
  • 共纳入171例患者,平均年龄70±14岁,女性占42%。
  • 术后第2天采集血样,用ELISA法检测S100B血清浓度;随访脑影像确定梗死体积;90天评估mRS功能结局。

主要发现

  • S100B水平与梗死体积相关。
  • 术后第2天S100B中位数在90天预后良好组(mRS 0-1)为0.10 µg/L(四分位距0.07-0.14),低于预后不良组(mRS 2-6)的0.20 µg/L(0.11-0.48),p < 0.001。
  • 较年轻年龄(OR 1.120 [CI 1.068-1.174];p < 0.001)、较低的症状发作后24小时NIHSS评分(OR 1.232 [CI 1.106-1.372];p < 0.001)和较低的S100B血清浓度(OR 1.364 [CI 1.105-1.683];p = 0.004)独立关联于良好预后。
  • S100B能够消除使用mRS评估卒中后90天功能结局时相关的侧化偏倚。

关键数值与推荐

  • 证据等级:Class I证据表明急性缺血性卒中机械取栓后第2天S100B能准确区分功能预后良好与不良。

临床怎么用

  • 取栓后第2天检测S100B血清浓度可快速辅助判断缺血组织损伤程度和功能预后。
  • S100B可作为不依赖脑影像和临床量表的客观替代结局指标,用于临床常规和介入试验。
  • S100B有助于消除mRS评估中的侧化偏倚。

局限性

  • 研究为前瞻性两中心设计,样本量有限(171例),需进一步前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To establish serum concentration of protein S100B as an objective biomarker surrogate for astroglial tissue damage after mechanical thrombectomy in patients with acute ischemic stroke. METHODS: This prospective 2-center study recruited patients with acute middle cerebral artery infarctions caused by large vessel occlusion treated with mechanical thrombectomy. Blood samples were collected at day 2 after intervention and analyzed for S100B serum concentrations using ELISA techniques. Infarct size was determined on follow-up brain imaging and functional outcome according to modified Rankin Scale (mRS) was assessed at 90 days. RESULTS: A total of 171 patients were included (mean age ± SD: 70 ± 14 years, 42% female). S100B levels correlated with infarct size. Median S100B concentrations at day 2 after intervention were lower in patients with favorable outcome (mRS score 0-1) at 90 days compared to patients with unfavorable outcome (mRS score 2-6) (median 0.10 µg/L [interquartile range 0.07-0.14] vs 0.20 µg/L [0.11-0.48], p < 0.001). Younger age (odds ratio [OR] 1.120 [confidence interval (CI) 1.068-1.174]; p < 0.001), lower National Institutes of Health Stroke Scale score 24 hours after symptom onset (OR 1.232 [CI 1.106-1.372]; p < 0.001), and lower S100B serum concentrations (OR 1.364 [CI 1.105-1.683]; p = 0.004) were independently associated with a favorable outcome. S100B was able to eliminate the lateralization bias associated with the use of mRS for functional outcome assessment at 90 days after stroke. DISCUSSION: S100B serum concentrations after mechanical thrombectomy indicate the extent of ischemic tissue damage. This can be assessed rapidly, independent of brain imaging and clinical outcome scales. Following prospective validation in further studies, this may provide an objective surrogate outcome measure both in clinical routine and interventional trials. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that S100B 2 days following mechanical thrombectomy for acute ischemic stroke accurately distinguishes favorable from unfavorable functional outcome.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Luger S, Koerbel K, Martinez Oeckel A, et al. Role of S100B Serum Concentration as a Surrogate Outcome Parameter After Mechanical Thrombectomy. Neurology. 2021. PMID: 34635559. doi:10.1212/WNL.0000000000012918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。